Login
$VERA
$26.97 -$1.13 (4.02%) Live

$VERA SEC Filings

Filed On Filing
16 Nov 2026 SCHEDULE 13G/A
16 Nov 2026 SCHEDULE 13G/A
16 Nov 2026 SCHEDULE 13G/A
10 Nov 2026 SCHEDULE 13G
05 Nov 2026 10-Q
05 Nov 2026 8-K: Results of Operations and Financial Condition

TRUTAKNA® (atacicept-vymj) U.S. launch building early momentum following July 7 accelerated approval by the U.S. Food and Drug Administration (FDA) with approximately 700 Patient Start Forms (PSFs) to date and $10.3 million of net produc...

17 Sep 2026 Form 4: Fordyce Marshall, Director

Received 18,500 shares by exercise or conversion ($53.6K) · Sold 18,500 shares ($685K)

15 Sep 2026 8-K: Regulation FD Disclosure; Other Events

Exhibit 99.2 Corporate Presentation Sep temb er 2026 © 2026 Vera Therapeutics, Inc. Corporate Presentation

14 Sep 2026 Form 4: Young Joseph R, SVP, FINANCE, CHIEF ACCT OFFCR

Received 5,000 shares by exercise or conversion ($19.7K)

04 Sep 2026 Form 4: Fordyce Marshall, Director

Received 18,500 shares by exercise or conversion ($53.6K) · Sold 18,500 shares ($650K)

02 Sep 2026 144
14 Aug 2026 SCHEDULE 13G/A
12 Aug 2026 Form 4/A: Fordyce Marshall, Director

Received 46,250 shares by exercise or conversion ($134K) · Sold 46,250 shares ($1.96M)

12 Aug 2026 Form 4/A: Fordyce Marshall, Director

Received 18,500 shares by exercise or conversion ($53.6K) · Sold 18,500 shares ($702K)

12 Aug 2026 Form 4/A: Fordyce Marshall, Director

Received 18,500 shares by exercise or conversion ($53.6K) · Sold 18,500 shares ($680K)

10 Aug 2026 10-Q
10 Aug 2026 8-K: Results of Operations and Financial Condition

TRUTAKNA™ granted accelerated approval by U.S. Food and Drug Administration (FDA) in adult patients with primary IgA nephropathy (IgAN) at risk for disease progression.

07 Aug 2026 SCHEDULE 13G
05 Aug 2026 Form 4: Boman Nancy Lee, Chief Regulatory Officer

Received 44,987 shares as a grant or award · Granted 63,011 Stock Option (right to buy)

05 Aug 2026 Form 3: Boman Nancy Lee, Chief Regulatory Officer

No securities owned

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support